Beyond LDL: Why ApoB and Lipoprotein(a) Are the Biomarkers That Matter

The problem with standard cholesterol testing

A standard lipid panel measures total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. These are genuinely useful markers — but they have a well-documented blind spot.

LDL cholesterol (LDL-C) measures the total amount of cholesterol carried inside LDL particles. What it does not measure is how many particles are actually circulating in your bloodstream. This distinction matters more than it first appears.

Two people can have an identical LDL-C result of, say, 3.0 mmol/L. One might have a smaller number of large, buoyant LDL particles carrying that cholesterol. The other might have a far greater number of smaller, denser particles carrying the same total amount. Those two individuals have very different numbers of atherogenic particles — and that difference translates into meaningfully different cardiovascular risk.

This phenomenon is sometimes called LDL-C and ApoB discordance — when LDL cholesterol content and LDL particle count point in different directions. It occurs most often in people with metabolic syndrome, insulin resistance, type 2 diabetes, or elevated triglycerides.

The clinical concept of residual cardiovascular risk captures what is left over: the ongoing heart attack and stroke risk that persists in some people even when their LDL-C appears controlled or within range. A significant portion of this residual risk is explained by elevated ApoB and Lp(a) — biomarkers that a standard lipid panel does not measure.

To be clear: a standard lipid panel is a valuable starting point, and most Australians benefit from knowing their LDL, HDL, and triglycerides. The goal of advanced lipid testing is not to replace these markers but to add a layer of precision where it is most needed.

What is ApoB and why does it matter?

Think of LDL cholesterol as measuring the total weight of cargo on a fleet of ships. Apolipoprotein B (ApoB) counts the ships themselves.

ApoB is a protein found on the surface of every atherogenic (plaque-forming) lipoprotein in your blood — including LDL, VLDL, IDL, and Lp(a). Crucially, each of these particles carries exactly one ApoB molecule. This means that measuring ApoB gives you a direct count of the total number of atherogenic particles circulating in your bloodstream.

Why does particle count matter?

• Atherosclerosis — plaque buildup in artery walls — is driven by atherogenic particles penetrating and becoming trapped in the arterial lining
• More particles means more opportunities for arterial penetration, regardless of how much cholesterol each individual particle carries
• A high particle count with a normal or low LDL-C (discordance) represents a hidden cardiovascular risk burden
• ApoB is not meaningfully affected by whether you fast before the test, making it practically easier to interpret than triglycerides

A 2021 Scientific Statement from the National Lipid Association concluded that ApoB often predicts cardiovascular risk more accurately than LDL-C, particularly in people with elevated triglycerides, insulin resistance, or metabolic syndrome (Wilson et al., *Journal of Clinical Lipidology*, 2021).

For practical purposes: a person with normal LDL-C but elevated ApoB has more atherogenic particles than their cholesterol level suggests. Their cardiovascular risk is higher than the standard lipid panel implies. This is the core reason ApoB is increasingly used alongside or instead of LDL-C in cardiovascular risk assessment.

Read more about how [ApoB is measured](/blogs/biomarker-pages/apolipoprotein-b) and what the test involves.

What is Lipoprotein(a)?

Lipoprotein(a) — written as Lp(a) and pronounced "LP little a" — is a unique lipoprotein that is almost entirely determined by genetics. Unlike LDL, triglycerides, or HDL, your Lp(a) level is set largely at birth and stays relatively stable throughout your life. Diet, exercise, and most medications have little impact on it.

Lp(a) is structurally similar to [LDL cholesterol](/blogs/biomarker-pages/ldl-c) — it also carries an ApoB protein — but it has an additional protein called apolipoprotein(a) attached to it. This additional protein makes Lp(a) particularly atherogenic and prothrombotic (clot-promoting), which amplifies cardiovascular risk beyond what LDL alone would predict.

Elevated Lp(a) is a significant independent risk factor for:

• Coronary artery disease (heart attack)
• Stroke
• Peripheral artery disease
• Aortic valve stenosis

According to FH Australia, approximately 1 in 5 people have elevated Lp(a) — and the vast majority are completely unaware of it. Most standard lipid panels in Australia do not routinely test Lp(a), meaning this risk factor often goes undetected until a cardiac event occurs.

Because Lp(a) is genetically determined, there is no current medication approved in Australia that reliably lowers it — though several investigational therapies are in advanced clinical trials internationally. The clinical value of knowing your Lp(a) level is not about lowering it directly, but about understanding your baseline risk so that all other modifiable risk factors (LDL-C, blood pressure, smoking, diabetes) can be managed more aggressively.

Read more about [Lipoprotein testing](/blogs/biomarker-pages/lipoprotein) and what Lp(a) specifically measures.

How these biomarkers improve cardiovascular risk assessment

The limitations of LDL-C are best understood through real-world patterns. Consider the following two scenarios where standard lipid panels may give incomplete information:

Scenario 1 — Low LDL-C, elevated ApoB: A 48-year-old man has LDL-C of 2.8 mmol/L (within target range), but his [triglycerides](/blogs/biomarker-pages/triglycerides) are elevated and he has central obesity. His ApoB comes back at 1.3 g/L — elevated, indicating a high number of small, dense LDL particles. A standard panel would have assessed him as lower risk. ApoB reveals the true particle burden.

Scenario 2 — Normal lipids, elevated Lp(a): A 42-year-old woman with no other risk factors has a heart attack. Retrospectively, her Lp(a) is found to be 180 nmol/L — markedly elevated. Her standard cholesterol panel was entirely normal. Without Lp(a) testing, there was no signal.

The concept of concordance vs discordance between LDL-C and ApoB is well established in the lipid literature. When LDL-C and ApoB align (both high or both low), the standard panel is reasonably reliable. When they diverge — LDL-C appears acceptable but ApoB is elevated — risk is underestimated.

Research published in the *Journal of the American College of Cardiology* (Johannesen et al., 2024) found that excess ApoB relative to LDL-C is a meaningful warning sign of hidden cardiovascular risk in both men and women.

The 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias (Mach et al., *European Heart Journal*, 2020) recognise ApoB as a secondary treatment target, particularly useful in people where LDL-C may underestimate risk. Lp(a) is also identified in these guidelines as a causal risk factor for atherosclerotic cardiovascular disease.

In Australia, advanced lipid testing — including ApoB and Lp(a) — is available through private pathology providers. It is not routinely ordered on Medicare for everyone, but it is accessible. Discuss with your GP whether your individual risk profile makes advanced lipid testing appropriate.

Understand your cardiovascular health more completely

A standard cholesterol test is a useful starting point — but it may not tell the whole story. Listen Health's comprehensive testing panel includes advanced cardiovascular markers including ApoB and Lp(a), so you can build a more complete picture of your heart health over time.

Start Testing Today

Developed by leading doctorsNo waiting, no referrals2,000+ locations Australia-wide

Australian reference ranges and what your results mean

In Australia, pathology results are reported in locally standardised units. Understanding which unit applies to each marker matters — and it is worth noting that Lp(a) can be reported in two different units depending on the laboratory.

ApoB reference ranges (Australian pathology, g/L):

• Desirable: < 1.0 g/L
• Borderline elevated: 1.0–1.2 g/L
• Elevated: > 1.2 g/L
• Optimal for high cardiovascular risk individuals: < 0.8 g/L

These values align with Australian pathology standards and the ESC/EAS 2019 Guidelines. For people with established cardiovascular disease or very high risk, a target below 0.65–0.8 g/L is increasingly used in clinical practice — discuss specific targets with your GP or cardiologist.

Lp(a) reference ranges (two units used in Australia):

• nmol/L (preferred): desirable below 75 nmol/L; elevated above 125 nmol/L
• mg/dL (also used): desirable below 30 mg/dL

Note that nmol/L and mg/dL do not convert with a simple fixed ratio — the conversion depends on the molecular weight of the specific Lp(a) isoform, which varies between individuals. If you receive results in one unit and see a reference range in another, clarify with your pathology provider rather than converting directly.

A few important distinctions to understand:

• Reference ranges (population-based cut-offs) and optimal targets are different things. Reference ranges are derived from population distributions. Optimal targets — particularly for ApoB in high-risk individuals — may be lower than the population "desirable" range.
• A result within the reference range does not necessarily mean no risk. It means the result is within the range seen in a general population sample. Your individual risk depends on all your risk factors together.
• Lp(a) levels are relatively stable across your lifetime. A single measurement provides a meaningful long-term risk signal — unlike LDL-C or triglycerides, which can fluctuate with diet and lifestyle.

Always refer to the reference ranges printed on your specific pathology report, as these may vary slightly between Australian laboratories.

Who should consider advanced lipid testing?

Advanced lipid testing — including ApoB and Lp(a) — is not currently recommended as a first-line universal screen in Australia. But there are clear situations where testing provides meaningful additional information.

Consider discussing ApoB testing with your GP if:

• Your LDL-C appears normal but you have other cardiovascular risk factors (hypertension, diabetes, smoking, obesity)
• Your triglycerides are elevated — this is the scenario most associated with LDL-C and ApoB discordance
• You have metabolic syndrome or insulin resistance
• You have a family history of premature cardiovascular disease (heart attack or stroke in a first-degree relative before age 60)
• You are on statin therapy and your doctor wants to monitor whether particle count is truly being controlled
• Your absolute cardiovascular risk score is borderline and you want to understand whether the risk is higher than the score suggests

Consider discussing Lp(a) testing with your GP if:

• You have a family history of heart attack, stroke, or premature cardiovascular disease that cannot be fully explained by conventional risk factors
• A family member has been found to have elevated Lp(a) — it is highly heritable (approximately 50% chance first-degree relatives will also have elevated levels, per FH Australia)
• You have been diagnosed with familial hypercholesterolaemia (FH) — the combination of FH and elevated Lp(a) significantly increases cardiovascular risk
• You have had a cardiovascular event (heart attack, stroke) and your standard lipid panel does not explain why
• You want a comprehensive understanding of your inherited cardiovascular risk profile

The RACGP Guidelines for Preventive Activities in General Practice (Red Book) emphasise a risk-based approach to cardiovascular screening. Advanced lipid testing is one tool within this broader framework — it adds precision where standard testing reaches its limits.

Read more about [HDL cholesterol](/blogs/biomarker-pages/hdl-cholesterol) and [total cholesterol](/blogs/biomarker-pages/total-cholestrol) as part of your complete lipid picture.

What you can do with your results

Understanding your ApoB or Lp(a) result is a starting point for an informed conversation with your GP — not a reason for alarm, and not a substitute for professional medical advice.

If your ApoB is elevated:

ApoB responds to many of the same lifestyle changes that lower LDL-C, and often more meaningfully:

• Reduce refined carbohydrates, added sugars, and ultra-processed foods — these drive small, dense LDL particle production
• Replace saturated fats (butter, fatty meat, coconut oil) with unsaturated fats (olive oil, nuts, avocado, oily fish)
• Increase soluble fibre intake (oats, legumes, psyllium) — it reduces LDL particle number
• Regular aerobic and resistance exercise improves particle clearance and reduces ApoB
• Manage weight, particularly central adiposity, which directly elevates ApoB through increased liver fat
• Discuss statin therapy with your GP if lifestyle changes are insufficient — statins are effective at lowering both LDL-C and ApoB

For people at high cardiovascular risk, newer medications — including PCSK9 inhibitors — can achieve substantial ApoB reductions beyond what statins alone achieve. This is a clinical decision for your GP or cardiologist.

If your Lp(a) is elevated:

The picture is different. Because Lp(a) is genetically determined and does not meaningfully respond to lifestyle, the focus shifts to managing all your other modifiable risk factors more aggressively:

• Treat LDL-C to lower targets than you might otherwise require
• Manage blood pressure closely
• Do not smoke — smoking compounds the already-elevated cardiovascular risk from high Lp(a)
• Manage blood glucose and insulin resistance
• Maintain a healthy weight and stay physically active
• Discuss your family history and inform first-degree relatives that they may also carry elevated Lp(a)

Several targeted Lp(a)-lowering therapies (RNA-based medicines) are in advanced clinical trials and may become available in Australia within the next few years. Your GP or a cardiologist can advise on whether enrolment in a clinical trial or monitoring for emerging therapies is relevant to your situation.

Read more about [high-sensitivity CRP](/blogs/biomarker-pages/high-sensitivity-c-reactive-protein-hs-crp) and [Apolipoprotein A1](/blogs/biomarker-pages/apolipoprotein-a1) as complementary cardiovascular risk markers.